396 related articles for article (PubMed ID: 23560990)
1. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation.
Ma S; Lin YY; He J; Rouhani FN; Brantly M; Turino GM
COPD; 2013 Aug; 10(4):473-81. PubMed ID: 23560990
[TBL] [Abstract][Full Text] [Related]
2. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.
Campos MA; Geraghty P; Holt G; Mendes E; Newby PR; Ma S; Luna-Diaz LV; Turino GM; Stockley RA
Am J Respir Crit Care Med; 2019 Aug; 200(3):318-326. PubMed ID: 30965011
[No Abstract] [Full Text] [Related]
3. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group.
Gottlieb DJ; Luisetti M; Stone PJ; Allegra L; Cantey-Kiser JM; Grassi C; Snider GL
Am J Respir Crit Care Med; 2000 Dec; 162(6):2069-72. PubMed ID: 11112116
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans.
Stone PJ; Morris TA; Franzblau C; Snider GL
Respiration; 1995; 62(2):76-9. PubMed ID: 7784713
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in Alpha-1 Antitrypsin Deficiency Chronic Obstructive Pulmonary Disease.
Turino GM; Ma S; Cantor JO; Lin YY
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S336-40. PubMed ID: 27564670
[TBL] [Abstract][Full Text] [Related]
6. Chronic Obstructive Pulmonary Disease. A Biomarker and a Potential Therapy.
Turino GM
Ann Am Thorac Soc; 2018 Feb; 15(Suppl 1):S15-S17. PubMed ID: 29461896
[TBL] [Abstract][Full Text] [Related]
7. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
8. A review of augmentation therapy for alpha-1 antitrypsin deficiency.
Mohanka M; Khemasuwan D; Stoller JK
Expert Opin Biol Ther; 2012 Jun; 12(6):685-700. PubMed ID: 22500781
[TBL] [Abstract][Full Text] [Related]
9. Measurements of desmosine and isodesmosine by mass spectrometry in COPD.
Ma S; Lin YY; Turino GM
Chest; 2007 May; 131(5):1363-71. PubMed ID: 17494786
[TBL] [Abstract][Full Text] [Related]
10. Alpha-1 antitrypsin: now available, but do we need it?
Russi EW
Swiss Med Wkly; 2008 Apr; 138(13-14):191-6. PubMed ID: 18389391
[TBL] [Abstract][Full Text] [Related]
11. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
Campos MA; Lascano J
Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
[TBL] [Abstract][Full Text] [Related]
12. Elastin degradation products as biomarkers in alpha-1 antitrypsin deficiency: lastin' impact?
Stoller JK
COPD; 2013 Aug; 10(4):403-4. PubMed ID: 23875739
[No Abstract] [Full Text] [Related]
13. The Therapeutic Potential of Hyaluronan in COPD.
Turino GM; Ma S; Lin YY; Cantor JO
Chest; 2018 Apr; 153(4):792-798. PubMed ID: 29289686
[TBL] [Abstract][Full Text] [Related]
14. Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals.
Hurley K; Lacey N; O'Dwyer CA; Bergin DA; McElvaney OJ; O'Brien ME; McElvaney OF; Reeves EP; McElvaney NG
J Immunol; 2014 Oct; 193(8):3978-91. PubMed ID: 25217166
[TBL] [Abstract][Full Text] [Related]
15. The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling.
O'Dwyer CA; O'Brien ME; Wormald MR; White MM; Banville N; Hurley K; McCarthy C; McElvaney NG; Reeves EP
J Immunol; 2015 Oct; 195(8):3628-41. PubMed ID: 26371243
[TBL] [Abstract][Full Text] [Related]
16. Pallid mice with genetic emphysema. Neutrophil elastase burden and elastin loss occur without alteration in the bronchoalveolar lavage cell population.
de Santi MM; Martorana PA; Cavarra E; Lungarella G
Lab Invest; 1995 Jul; 73(1):40-7. PubMed ID: 7603039
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro.
Geraghty P; Rogan MP; Greene CM; Brantly ML; O'Neill SJ; Taggart CC; McElvaney NG
Thorax; 2008 Jul; 63(7):621-6. PubMed ID: 18250185
[TBL] [Abstract][Full Text] [Related]
19. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.
Lieberman J
Chest; 2000 Nov; 118(5):1480-5. PubMed ID: 11083705
[TBL] [Abstract][Full Text] [Related]
20. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease.
Turino GM; Ma S; Lin YY; Cantor JO; Luisetti M
Am J Respir Crit Care Med; 2011 Sep; 184(6):637-41. PubMed ID: 21757624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
